替罗非班治疗急性脑梗死溶栓后再闭塞患者的效果  

Clinical Effects of Tirofiban in the Treatment of Re Occlusion After Thrombolysis of Acute Cerebral Infarction

作　　者：殷卓琳[1] YIN Zhuo-Lin(Department of Neurology,Jilin People's Hospital,Changchun 130021,China)

机构地区：[1]吉林省人民医院神经内科,长春130021

出　　处：《中国药物经济学》2020年第9期116-118,共3页China Journal of Pharmaceutical Economics

摘　　要：目的探讨替罗非班治疗急性脑梗死溶栓后再闭塞患者的效果。方法选取吉林省人民医院神经内科2018年10月至2019年10月收治的急性脑梗死溶栓后再闭塞患者124例作为研究对象,随机分为观察组与对照组,每组62例。两组患者采用阿替普酶静脉溶栓治疗,同时观察组给予替罗非班治疗,对照组给予常规治疗,比较两组患者的治疗效果。结果观察组患者治疗有效率为93.55%,对照组患者治疗有效率为79.03%,差异有统计学意义(P<0.05);观察组溶栓后24 h、7 d、3个月的美国国立卫生研究院卒中量表(NIHSS)评分分别为(8.44±2.27)分、(6.32±1.56)分、(4.72±0.89)分,显著低于对照组,日常生活活动能力(ADL)评分(60.17±4.36)分,显著高于对照组,差异有统计学意义(P<0.05);观察组不良事件发生率(8.06%)和死亡率(0.00%)显著低于对照组12.90%、3.23%,差异有统计学意义(P<0.05)。结论将替罗非班应用于急性脑梗死溶栓后再闭塞治疗中,能有效降低血栓形成,促进患者神经功能恢复,减少不良事件和死亡率发生,改善预后。Objective To explore the effects of tirofiban in the treatment of re occlusion of acute cerebral infarction after thrombolysis. Methods From October 2018 to October 2019, one hundred and twenty-four patients with acute cerebral infarction and re occlusion after thrombolysis admitted to Department of Neurology, Jilin People’s Hospital were selected as the research objects and were randomly divided into an observation group and a control group, with sixty-two cases in each group. All patients were treated by intravenous thrombolysis with ateplase. The observation group was treated with tirofiban and the control group was given routine treatment. The treatment effect of the two groups of patients were compared. Results The effective rate of the observation group was 93.55%, and the effective rate of the control group was 79.03%, there was statistical significance between the two groups(P<0.05);the National Institutes of Health Stroke Scale(NIHSS) scores of the observation group were(8.44±2.27) score,(6.32±1.56) score and(4.72±0.89) socre 24 hours, 7 days and 3 months after treatment, respectively, which were significantly lower than those of the control group. ADL score(60.17±4.36) was significantly higher than that of the control group and the difference was statistically significant(P<0.05);the incidence of adverse events(8.06%) and mortality(0.00%) in the observation group was significantly lower than those in the control group(12.90% and 3.23%) and the difference was statistically significant(P<0.05). Conclusion Tirofiban was used in the treatment of acute cerebral infarction. It can effectively reduce thrombosis, promote the recovery of patients’ neurological function, reduce the incidence of adverse events and mortality, and improve the prognosis.

关 键 词：替罗非班 急性脑梗死 溶栓后再闭塞 效果 

分 类 号：R743.3[医药卫生—神经病学与精神病学] R971[医药卫生—临床医学]